Teresa Auguet1,2, Gemma Aragonès1, Alba Berlanga1, Salomé Martínez3, Fàtima Sabench4, Carmen Aguilar1, Beatriz Villar2, Joan Josep Sirvent3, Daniel Del Castillo4, Cristóbal Richart1,2. 1. Research Group on Metabolic Diseases and Insulin Resistance, Department of Medicine and Surgery, Pere Virgili Institute of Health Research, Rovira i Virgili University, Tarragona, Spain. 2. Internal Medicine Service, Joan XXIII University Hospital Tarragona, Tarragona, Spain. 3. Pathological Anatomy Service, Joan XXIII University Hospital Tarragona, Tarragona, Spain. 4. Surgery Service, Department of Medicine and Surgery, Sant Joan de Reus Hospital, Pere Virgili Institute of Health Research, Rovira i Virgili University, Reus, Spain.
Abstract
OBJECTIVE: This study was performed to investigate neurotensin plasma levels in patients with nonalcoholic fatty liver disease (NAFLD) associated with severe obesity. METHODS: The plasma levels of neurotensin in 20 women with normal weight and 51 women with morbid obesity (MO) were measured, and women were subclassified according to their hepatic histology as having MO without NAFLD (n = 18) or MO with NAFLD (n = 33). The NAFLD group included 15 women with simple steatosis (SS) and 18 women with nonalcoholic steatohepatitis (NASH). To quantify neurotensin in plasma, a multiplex sandwich immunoassay with a Luminex magnetic bead-based platform was used. RESULTS: Neurotensin levels were significantly decreased (P = 0.001) in women with MO and NAFLD (3.62 ± 0.85 ng/mL), compared with women with MO and normal liver function (11.65 ± 1.95 ng/mL; P = 0.001) and women with normal weight (13.68 ± 2.58 ng/mL; P = 0.001). There was no difference in levels between women with SS and women with NASH (P = 0.415). CONCLUSIONS: Circulating levels of neurotensin were decreased in women with NAFLD associated with MO.
OBJECTIVE: This study was performed to investigate neurotensin plasma levels in patients with nonalcoholic fatty liver disease (NAFLD) associated with severe obesity. METHODS: The plasma levels of neurotensin in 20 women with normal weight and 51 women with morbid obesity (MO) were measured, and women were subclassified according to their hepatic histology as having MO without NAFLD (n = 18) or MO with NAFLD (n = 33). The NAFLD group included 15 women with simple steatosis (SS) and 18 women with nonalcoholic steatohepatitis (NASH). To quantify neurotensin in plasma, a multiplex sandwich immunoassay with a Luminex magnetic bead-based platform was used. RESULTS:Neurotensin levels were significantly decreased (P = 0.001) in women with MO and NAFLD (3.62 ± 0.85 ng/mL), compared with women with MO and normal liver function (11.65 ± 1.95 ng/mL; P = 0.001) and women with normal weight (13.68 ± 2.58 ng/mL; P = 0.001). There was no difference in levels between women with SS and women with NASH (P = 0.415). CONCLUSIONS: Circulating levels of neurotensin were decreased in women with NAFLD associated with MO.
Authors: Cecilia Ratner; Zhenyan He; Kaare V Grunddal; Louise J Skov; Bolette Hartmann; Fa Zhang; Annette Feuchtinger; Anette Bjerregaard; Christina Christoffersen; Matthias H Tschöp; Brian Finan; Richard D DiMarchi; Gina M Leinninger; Kevin W Williams; Christoffer Clemmensen; Birgitte Holst Journal: Diabetes Date: 2019-04-01 Impact factor: 9.461
Authors: Beatriz Villar; Laia Bertran; Carmen Aguilar; Jessica Binetti; Salomé Martínez; Fàtima Sabench; Monica Real; David Riesco; Marta París; Daniel Del Castillo; Cristóbal Richart; Teresa Auguet Journal: Metabolites Date: 2021-06-10